T. Lepilkina

发表

Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study

M. Morozova, Y. Lavrovsky, A. Ivachtchenko, 2013, CNS Spectrums.

Double-blind placebo-controlled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission.

M. Morozova, A. Beniashvili, G. Rupchev, 2012, Psychiatria Danubina.

Effects of Blockade of Cholinesterase on Negative Disorders in Schizophrenia

M. Morozova, A. Beniashvili, D. Burminskiy, 2022, Neuroscience and Behavioral Physiology.

[An effect of cholinesterase blockade on negative symptoms in schizophrenia].

M. Morozova, G. Rupchev, A. Beniashvili, 2021, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.